Market Overview - The S&P 500 and Nasdaq experienced declines due to pressure on Big Tech following CoreWeave's disappointing quarterly results, which included a lowered revenue outlook, leading to a 14% drop in CoreWeave's shares [1] - Wall Street is also reacting to soft labor market data, with ADP's payroll tracker indicating an average decline of 11,250 jobs over the four weeks ending October 25 [1] Company-Specific Updates - Linde's shares rose over 1% after UBS upgraded the company from a hold-equivalent rating to a buy, despite a price target reduction from $507 to $500, citing expected earnings-per-share growth in 2026 as a positive catalyst [1] - Nvidia's stock fell approximately 3% after SoftBank announced the sale of its entire stake in the company, which is part of a strategy to fund a $22.5 billion investment in OpenAI; this development does not raise concerns for Nvidia, maintaining the "own, don't trade" thesis [1] Additional Insights - The rapid-fire segment at the end of the video covered stocks including CoreWeave, Paramount Skydance, Amgen, Dutch Bros, and Coterra Energy [1] - Jim Cramer will be signing copies of his new book on market strategies, indicating ongoing engagement with investors [1]

Let's get right to the opening bell in the CNBC real time exchange at the big board. It's neuroscience alto neuroscience using AI to develop medications for neurological diseases at the NASDAQ as you saw before aboard the USS Intrepid, Senator Jerry Moran, chairman of uh Veterans Affairs, and Mona Dexter, VP of military and veteran affairs for Comcast, which has done a lot of good work with veterans over the years. >> Yeah, it's interesting.You're seeing a lot of companies trying to do neurological. Neurolo ...

Core Insights - The data presented indicates that lowering LDL cholesterol to a median target of 45 can reduce the risk of a first heart attack by 36% in the studied subjects [2][3] - The trial demonstrates that adding the drug Rapatha to optimized therapy can significantly prevent first occurrences of heart attacks and strokes, as well as potentially reduce cardiac death [2][3] Group 1: LDL Cholesterol and Heart Health - There is no level of cholesterol that is considered good, and the only way to achieve significant reduction is through medication [1] - The trial results confirm that lower LDL cholesterol levels are beneficial, with a targeted median of 45 showing meaningful benefits compared to a placebo group [3] Group 2: Drug Efficacy - The addition of Rapatha to existing therapies has shown a strong potential in preventing major heart-related issues, marking a significant advancement in treatment options [2][3]

Core Insights - The third-quarter 2025 reporting cycle for the Medical sector, which includes pharma/biotech and medical device companies, is nearing completion [1] Earnings Performance - Major pharmaceutical companies like Amgen, Novo Nordisk, and Pfizer reported earnings, with Amgen and Pfizer showing strong results and raising their EPS outlook for 2025, while Novo Nordisk faced weaker-than-expected results and reduced its full-year guidance due to slower growth in its GLP-1 portfolio [2] - As of November 5, nearly 82% of companies in the Medical sector, representing 92% of the sector's market capitalization, reported quarterly earnings, with approximately 92% beating earnings estimates and around 84% exceeding revenue expectations. Year-over-year earnings rose over 4%, while revenues increased nearly 11%, with overall expected increases of 3.0% in earnings and 10.5% in sales compared to the previous year [3] Potential Earnings Surprises - Four biotech companies—Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma, and Immuneering—are highlighted as likely to deliver earnings beats based on their positive Earnings ESP and solid Zacks ranks [4][10] - Alto Neuroscience has an Earnings ESP of +16.41% and a Zacks Rank 2, with a consensus estimate for a loss of 66 cents per share [7] - Autolus Therapeutics has an Earnings ESP of +22.30% and a Zacks Rank 2, with a consensus estimate for a loss of 23 cents per share [11] - Ascendis Pharma has an Earnings ESP of +34.28% and a Zacks Rank 3, with a consensus estimate for a loss of 41 cents per share [13] - Immuneering has an Earnings ESP of +21.62% and a Zacks Rank 3, with a consensus estimate for a loss of 37 cents per share [15]

Core Insights - Merck's new oral cholesterol-lowering pill, enlicitide, has shown a nearly 60% reduction in LDL cholesterol, positioning it as a potential competitor in the $47 billion cholesterol treatment market by 2033 [2][4]. Group 1: Product Development and Efficacy - Enlicitide works by blocking the PCSK9 protein, which is linked to elevated LDL cholesterol levels and cardiovascular issues [2]. - In a study involving 2,912 patients who could not achieve LDL goals with traditional treatments, enlicitide demonstrated a 55.8% greater reduction in LDL cholesterol compared to placebo, with a placebo-adjusted reduction of 59.7% after excluding an outlier [4]. - Other cardiovascular risk factors, including total cholesterol and markers like ApoB and Lp(a), also decreased, and enlicitide's safety profile was comparable to that of the placebo [5]. Group 2: Market Position and Competition - Merck plans to seek FDA approval for enlicitide in early 2026, aiming to compete with injectable PCSK9 inhibitors like Repatha and Praluent, which have historically faced challenges in market adoption [5]. - Repatha's sales increased by 40% year-over-year to $794 million, while Praluent's sales rose nearly 13% to $215.7 million in the third quarter, indicating a strong market presence for these injectable treatments [6]. Group 3: Patient Accessibility and Usage - Enlicitide is designed to be more accessible, requiring patients to fast for 30 minutes before taking the pill, with 97% of patients able to comply with this requirement [7]. - The ease of use and safety profile of enlicitide could significantly impact public health by providing a viable treatment option for a broader range of patients [8].

Core Insights - Amgen's Repatha (evolocumab) has shown significant reductions in major adverse cardiovascular events (MACE) in high-risk adults without prior heart attacks or strokes, marking it as the first PCSK9 inhibitor to achieve this [1][2][6] Clinical Trial Results - The Phase 3 VESALIUS-CV trial involved over 12,000 patients with atherosclerosis or diabetes, demonstrating a 25% relative reduction in the risk of coronary heart disease death, heart attack, or ischemic stroke (3-P MACE) and a 19% reduction in a broader composite including ischemia-driven revascularization (4-P MACE) [1][6] - Repatha reduced the risk of heart attack by 36% and achieved a median LDL-C level of 45 mg/dL compared to 109 mg/dL in the placebo group [1][6] Importance of LDL-C Management - The results emphasize the critical need for intensive LDL-C lowering to reduce cardiovascular risk, particularly in patients with diabetes who are often undertreated [2][3] - The American Diabetes Association highlights the importance of managing LDL-C in primary care settings to address cardiovascular disease, which is a leading cause of mortality among diabetic patients [3] Market and Accessibility - Repatha has been used by over 6.7 million patients globally since its approval in 2015, with recent FDA approvals expanding its use to adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C [5][6] - AmgenNow, a direct-to-patient program, offers Repatha at a monthly price of $239, significantly lower than the previous U.S. list price [5] Commitment to Cardiovascular Innovation - Amgen is dedicated to advancing cardiovascular care through innovative treatments targeting various risk factors associated with cardiovascular disease [6][10] - The company has a robust pipeline of investigational treatments aimed at improving patient outcomes in cardiovascular health [6][10]

Core Insights - Amgen's cholesterol drug Repatha has demonstrated a 25% reduction in major cardiovascular events for at-risk patients who have never experienced a heart attack or stroke [1] Group 1 - The addition of Repatha to standard therapy significantly benefits patients at risk for cardiovascular events [1]

Core Insights - Amgen, Inc. is one of the largest biotechnology companies in America and globally [1] Company Performance - The stock performance of Amgen has been quite volatile over the past 52 weeks [1]

Core Insights - Amgen, Inc. is one of the largest biotechnology companies in America and globally [1] Company Performance - The stock performance of Amgen has been quite volatile over the past 52 weeks [1]

Welcome to CBC. com. I'm Frank Colin, anchor of Worldwide Exchange.We are taking a look at the ETF market, which as of today has $1.13% trillion in net inflows, just a tick below the record set last year. And we are on pace for another record year this year. With that, I want to bring in my guest for today.It's Anaket Ulfra, head of their ETF business. Anakette, thanks for joining us. >> Thanks for having me, Frank.Um, first off, let me talk to you about the fact that ETF inflows are going to hit a record f ...